Global Alternative Splicing Defects in Human Breast Cancer Cells

被引:6
|
作者
Oh, Jagyeong [1 ]
Pradella, Davide [2 ]
Kim, Yoonseong [1 ]
Shao, Changwei [3 ]
Li, Hairi [3 ]
Choi, Namjeong [1 ]
Ha, Jiyeon [1 ]
Di Matteo, Anna [2 ]
Fu, Xiang-Dong [3 ]
Zheng, Xuexiu [1 ]
Ghigna, Claudia [2 ]
Shen, Haihong [1 ]
机构
[1] Gwangju Inst Sci & Technol, Sch Life Sci, Gwangju 500712, South Korea
[2] CNR, Inst Mol Genet Luigi Luca Cavalli Sforza, Via Abbiategrasso 207, I-27100 Pavia, Italy
[3] Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA
基金
新加坡国家研究基金会;
关键词
alternative splicing; breast cancer; exon skipping; intrinsically disordered regions; INTRINSICALLY DISORDERED REGIONS; MECHANISMS; MUTATIONS; LINE; CLASSIFICATION; ASSOCIATION; EXPRESSION; THERAPY; REVEALS;
D O I
10.3390/cancers13123071
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Aberrant alternative splicing (AS) regulation plays a pivotal role in breast cancer development, progression, and resistance to therapeutical interventions. Indeed, cancer cells can adapt their own transcriptome by changing different AS programs, thus generating cancer-specific AS isoforms involved in every hallmark of cancer. Here, we investigated global AS errors occurring in human breast cancer cells by using RNA-mediated oligonucleotide annealing, selection, and ligation coupled with next-generation sequencing. Our results identified several dysregulated AS events potentially relevant for breast cancer-related biological processes and that provide a better comprehension of the molecular mechanisms that orchestrate the malignant transformation. Breast cancer is the most frequently occurred cancer type and the second cause of death in women worldwide. Alternative splicing (AS) is the process that generates more than one mRNA isoform from a single gene, and it plays a major role in expanding the human protein diversity. Aberrant AS contributes to breast cancer metastasis and resistance to chemotherapeutic interventions. Therefore, identifying cancer-specific isoforms is the prerequisite for therapeutic interventions intended to correct aberrantly expressed AS events. Here, we performed RNA-mediated oligonucleotide annealing, selection, and ligation coupled with next-generation sequencing (RASL-seq) in breast cancer cells, to identify global breast cancer-specific AS defects. By RT-PCR validation, we demonstrate the high accuracy of RASL-seq results. In addition, we analyzed identified AS events using the Cancer Genome Atlas (TCGA) database in a large number of non-pathological and breast tumor specimens and validated them in normal and breast cancer samples. Interestingly, aberrantly regulated AS cassette exons in cancer tissues do not encode for known functional domains but instead encode for amino acids constituting regions of intrinsically disordered protein portions characterized by high flexibility and prone to be subjected to post-translational modifications. Collectively, our results reveal novel AS errors occurring in human breast cancer, potentially affecting breast cancer-related biological processes.
引用
收藏
页数:18
相关论文
共 50 条
  • [41] Characterization of alternative splicing events and prognostic signatures in breast cancer
    Han, Pihua
    Zhu, Jingjun
    Feng, Guang
    Wang, Zizhang
    Ding, Yanni
    BMC CANCER, 2021, 21 (01)
  • [42] TMEM16A alternative splicing coordination in breast cancer
    Ifeoma Ubby
    Erica Bussani
    Antonio Colonna
    Giuseppe Stacul
    Martina Locatelli
    Paolo Scudieri
    Luis Galietta
    Franco Pagani
    Molecular Cancer, 12
  • [43] Overexpression and alternative splicing of NF-YA in breast cancer
    Diletta Dolfini
    Valentina Andrioletti
    Roberto Mantovani
    Scientific Reports, 9
  • [44] The landscape of hypoxia-driven alternative splicing in breast cancer
    Choudhry, Hani
    Oikonomopoulos, Spyridon
    Yu, Peng
    Ivan, Cristina
    Ivan, Mircea
    Harris, Adrian L.
    Ragoussis, Jiannis
    CANCER RESEARCH, 2017, 77
  • [45] Alternative splicing of ALDOA confers tamoxifen resistance in breast cancer
    Yu, Shiyi
    Wu, Rui
    Si, Yue
    Fan, Zhehao
    Wang, Ying
    Yao, Chang
    Sun, Rongmao
    Xue, Yaji
    Chen, Yongli
    Wang, Zheng
    Dong, Shuangshuang
    Wang, Ning
    Ling, Xinyue
    Liang, Zhengyan
    Bi, Caili
    Yang, Yi
    Dong, Weibing
    Sun, Haibo
    ONCOGENE, 2024, 43 (39) : 2901 - 2913
  • [46] Alternative Splicing in Breast Cancer and the Potential Development of Therapeutic Tools
    Martinez-Montiel, Nancy
    Anaya-Ruiz, Maricruz
    Perez-Santos, Martin
    Martinez-Contreras, Rebeca D.
    GENES, 2017, 8 (10)
  • [47] TMEM16A alternative splicing coordination in breast cancer
    Ubby, Ifeoma
    Bussani, Erica
    Colonna, Antonio
    Stacul, Giuseppe
    Locatelli, Martina
    Scudieri, Paolo
    Galietta, Luis
    Pagani, Franco
    MOLECULAR CANCER, 2013, 12
  • [48] Alternative Splicing and Cancer
    Auboeuf, Didier
    Carmo-Fonseca, Maria
    Valcarcel, Juan
    Biamonti, Giuseppe
    JOURNAL OF NUCLEIC ACIDS, 2012, 2012
  • [49] SRPK1 acetylation modulates alternative splicing to regulate cisplatin resistance in breast cancer cells
    Wang, Cheng
    Zhou, Zhihong
    Subhramanyam, Charannya Sozheesvari
    Cao, Qiong
    Heng, Zealyn Shi Lin
    Liu, Wen
    Fu, Xiangdong
    Hu, Qidong
    COMMUNICATIONS BIOLOGY, 2020, 3 (01)
  • [50] SRPK1 acetylation modulates alternative splicing to regulate cisplatin resistance in breast cancer cells
    Cheng Wang
    Zhihong Zhou
    Charannya Sozheesvari Subhramanyam
    Qiong Cao
    Zealyn Shi Lin Heng
    Wen Liu
    Xiangdong Fu
    Qidong Hu
    Communications Biology, 3